Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints ...

SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.

Simufilam misses key endpoints again, prompting Cassava to phase out Alzheimer's program and shift to new indications ...

Under the terms of the agreements, Sava Re will provide up to $10m (€9.25m) in line size for ASR's core classes.

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...

Cassava Sciences, Inc. (SAVA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Cassava Sciences, Inc. (NASDAQ:SAVA) stands against other best ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Africa Specialty Risks (ASR) has entered binding authority agreements with Slovenia-based reinsurance company Sava Re. Under the terms of the agreements, Sava Re will provide up to $10m in line ...